(Reuters) – Soleno Therapeutics said on Wednesday it is aware of the death of a 17 year old male who was on the company’s treatment for patients who experience feelings of intense and persistent hunger, sending its shares down 10%.
Soleno said the treating physician has reported that the death is not related to the treatment Vykat XR.
Vykat treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder caused by full or partial deletions on chromosome 15 that affect the regulation of gene expression, or how genes turn on and off.
Soleno said the patient, who also suffered from obesity and other diseases, died from an apparent pulmonary embolus, a blockage in a lung artery usually caused by a blood clot.
The company said the incident has been reported in the U.S. Food and Drug Administration’s public dashboard called the FDA Adverse Event Reporting System.
(Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona)
Brought to you by www.srnnews.com
